Literature DB >> 12663271

Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men.

Chris J Hukshorn1, Margriet S Westerterp-Plantenga, Wim H M Saris.   

Abstract

BACKGROUND: Increasing evidence suggests that falling leptin concentrations observed during fasting act as a peripheral signal of starvation, which serves to conserve energy in the face of limited reserves. An extension of this hypothesis is that exogenous leptin should affect energy regulation during severe energy restriction.
OBJECTIVE: To explore this hypothesis, we assessed whether elevated leptin concentrations achieved with the use of long-acting pegylated human recombinant leptin [polyethylene glycol-OB protein (PEG-OB)] affected weight loss and changes in body composition, energy expenditure, appetite, and metabolic variables during semistarvation in healthy overweight men.
DESIGN: A randomized, double-blind, placebo-controlled study was executed in overweight men with a mean (+/- SEM) age of 34.8 +/- 1.3 y and body mass index (in kg/m2) of 28.8 +/- 0.5. All subjects received weekly treatment with 80 mg PEG-OB (n = 12) or matching placebo (n = 10) for 46 d while their energy intake was reduced to 2.1 MJ/d by means of a very-low-energy diet. Body composition (hydrodensitometry and deuterium dilution), energy expenditure (ventilated hood), and appetite (visual analogue scales) were evaluated at the start and the end of the study. Metabolic variables were measured throughout the study period.
RESULTS: Compared with placebo treatment, treatment with PEG-OB led to significant (P < 0.03) additional weight loss (14.6 +/- 0.8 compared with 11.8 +/- 0.9 kg) and a reduction in appetite (P < 0.05) after 46 d, but the 2 treatment groups did not differ significantly in changes in body composition, energy expenditure, and metabolic variables.
CONCLUSION: Our observations support the hypothesis that the decrease in leptin concentrations during starvation increases appetite in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663271     DOI: 10.1093/ajcn/77.4.771

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  22 in total

1.  Repositioning leptin as a therapy for Alzheimer's disease.

Authors:  Jane M Johnston; Steven J Greco; Ashkan Hamzelou; J Wesson Ashford; Nikolaos Tezapsidis
Journal:  Therapy       Date:  2011-09

Review 2.  The metabolic consequences of sleep deprivation.

Authors:  Kristen L Knutson; Karine Spiegel; Plamen Penev; Eve Van Cauter
Journal:  Sleep Med Rev       Date:  2007-04-17       Impact factor: 11.609

Review 3.  Associations between sleep loss and increased risk of obesity and diabetes.

Authors:  Kristen L Knutson; Eve Van Cauter
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 4.  20 years of leptin: role of leptin in energy homeostasis in humans.

Authors:  Michael Rosenbaum; Rudolph L Leibel
Journal:  J Endocrinol       Date:  2014-07-25       Impact factor: 4.286

5.  Decrease in hepatic very-low-density lipoprotein-triglyceride secretion after weight loss is inversely associated with changes in circulating leptin.

Authors:  F Magkos; E Fabbrini; J McCrea; B W Patterson; J C Eagon; S Klein
Journal:  Diabetes Obes Metab       Date:  2010-07       Impact factor: 6.577

Review 6.  Molecular determinants of the cardiometabolic phenotype.

Authors:  Lisa de las Fuentes; Giovanni de Simone; Donna K Arnett; Víctor G Dávila-Román
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-06       Impact factor: 2.895

Review 7.  The role of leptin in health and disease.

Authors:  Angela M Ramos-Lobo; Jose Donato
Journal:  Temperature (Austin)       Date:  2017-05-26

8.  The Role of Leptin in Maintaining Plasma Glucose During Starvation.

Authors:  Rachel J Perry; Gerald I Shulman
Journal:  Postdoc J       Date:  2018-03

Review 9.  The role of leptin in obesity and the potential for leptin replacement therapy.

Authors:  Helin Feng; Lihua Zheng; Zhangying Feng; Yaheng Zhao; Ning Zhang
Journal:  Endocrine       Date:  2012-12-29       Impact factor: 3.633

10.  Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity.

Authors:  Jean L Chan; Shekman L Wong; Christos S Mantzoros
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.